COVID-19: FDA Approves First Herbal Medicine For Clinical Trial

Food and Drugs Authority (FDA), Ghana

The Food and Drugs Authority (FDA) has announced that it has approved the first herbal medicine for clinical trials on COVID-19 treatment.

“The Food and Drugs Authority (FDA), the National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021,” it said in a statement issued on February 1, 2021.

The herbal medicine, Cryptolepis sanguinolenta, was submitted by researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology (KNUST) in September 2020 to assess its safety and efficacy as a potential treatment for COVID-19.

The FDA stated that “after a detailed assessment of the application gave the requisite regulatory authority for the conduct of the trial as per the mandate outlined under Part 8 (Section 150-166) of the Public Health Act 2012 (Act 851), which gives the Authority the legal mandate to regulate clinical trials of drugs, herbal medicinal products, cosmetics or medical devices.”

The FDA further stated that the trial will be conducted at two sites, adding that the sites have adequate capacity to ensure the safety of participants as well as produce credible scientific data.

Below is a copy of the full statement:


Click on the comment box below and leave us your thoughts. Thank you


Please enter your comment!
Please enter your name here